Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, Life Technologies Corporation launched the Oncomine Next Gen Sequencing Power Tools. This innovative offering from the company is an analytical tool to enable in-depth analysis of next generation sequencing (NGS) data for oncology research.

The NGS data is sourced from the data from The Cancer Genome Atlas. NGS is capable of providing insights into the factors inducing cancer. To date, over 4,500 paired tumor and samples have been analyzed.

The Oncomine NGS Power Tools is an accretive addition to Life’s Power Tools line of products. Moreover, this innovative offering from the company reflects its ability to cater to the broader needs of the cancer research space.

The Oncomine portfolio was included in the company’s profile following the takeover of Compendia Bioscience in Oct 2012. Earlier this year, in April, Life introduced its Oncomine Gene Browser and Ion Reporter Oncomine Workflow. The Oncomine Gene Browser is targeting the academic and smaller biotech market.  

About Oncomine NGS Power Tools

Life’s latest portfolio addition comprises an array of software tools that will allow researchers to assess novel predicted driver mutations and gene fusions for all types of cancer. The Oncomine NGS Power Tools will allow cancer researchers access to extensive recent data.

According to the company, investigators using the NGS Power Tools identified FGFR gene fusions across different cancer types. The nine distinguished tumor types uncovered by scientists at Life are lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer.

Our Take

Following the disclosure of its acquisition by Thermo Fisher Scientific Inc. (TMO - Analyst Report), Life sharpened focus on its product platform. We believe that the buyout will leverage Life’s attractive revenue profile. The acquisition is expected to close in early 2014.

Given Life’s expansive line of consumables for genomic, and molecular and cell biology, the takeover will complement Thermo Fisher’s market-leading portfolio of analytical technologies and specialty diagnostics.

However, with the current stock price reflecting the potential upsides, Life carries a Zacks Rank #4 (Sell). While the upsides are already built into Life’s shares, we are more positive about other medical stocks such as Haemonetics Corporation (HAE - Analyst Report) and Myriad Genetics Inc. (MYGN - Analyst Report). These stocks carry a favorable Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%